Abstract:e13651 Background: With the general application of EGFR TKI in treatment for NSCLC, more and more adherent and acquired resistance to such agents happens. To further improve efficacy of this kind of agents, a better understanding of the mechanism of resistance is necessary. Methods: Gefitinib-resistant PC9/G cell lines was induced by exposure of PC9 cell lines to MNNG and gefitinib and maintained in the mediua containing 0.05 umol/L of gefitinib. The inhibitory effects of gefitinib and/or LY294002 and PD98059 on cellular proliferation were tested by MTT assay. Cell cycle and apoptosis were analyzed by flow cytometry. Western Blot was used to detect expression of EGFR, phospho-EGFR, Akt and phospho-Akt. The different profiles of gene expression between PC9 and PC9/G cells were obtained by DNA microarray. β1 integrin was knocked down by transiently transfected siRNA. A scrambled sequence was used as control. The sensitivity to gefitinib of transfected cells was determined by MTT assay. Sequencing products were amplified by nested PCR. Apoptosis of transfected cells was assayed by TUNEL methods. Results: Resistant index of PC9/G to gefitinib was about 140 to 241 fold compared with PC9.Overexpression of β1 integrin was observed in PC9/G. Depletion of β1 integrin with shRNA results in inhibition of proliferation and promotion of apoptosis of PC9/G. Phosphorylation of Akt was less inhibited by gefitinib in PC9/G than in PC9. The restoration of sensitivity of PC9/G to gefitinib by LY294002, PI3-K inhibitor, and the diminished level of phospho-Akt induced by knock down of β1 integrin with RNAi. Conclusions: These findings suggest that β1 integrin signaling through PI3-K may be an important mechanism of resistance to EGFR TKIs and β1 integrin may be a therapeutic target for treatment of NSCLC unresponsive to EGFR inhibitors. No significant financial relationships to disclose.

Docosahexaenoic Acid Serving As Sensitizing Agents and Gefitinib Resistance Revertants in EGFR Targeting Treatment

Dha Increases The Anti-Tumor Effect Of Gefitinib On Non-Small Cell Lung Cancer With Egfr Mutations In Vitro

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells

Pharmacological Synergism of 2,2-Dichloroacetophenone and EGFR-TKi to Overcome TKi-induced Resistance in NSCLC Cells.

[Sensitivity of Two Cell Lines with Acquired Resistance to Gefitinib to Several Chemotherapeutic Drugs].

Chitosan-derived nanoparticles impede signal transduction in T790M lung cancer therapy.

The effects of cetuximab in combination with docetaxel for the acquired resistance to EGFR-TKI in non-small cell lung cancer cells

Pronounced Enhancement in Radiosensitization of Esophagus Cancer Cultivated in Docosahexaenoic Acid via the PPAR - γ Activation

Beta 1 Integrin Mediated Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Lung Cancer Cells

Eliminating Radiation Resistance of Non-Small Cell Lung Cancer by Dihydroartemisinin Through Abrogating Immunity Escaping and Promoting Radiation Sensitivity by Inhibiting PD-L1 Expression

Synergistic Antitumor Activity of DHA and JQ1 in Colorectal Carcinoma

The Targeting Mechanism of Dha Ligand and Its Conjugate with Gemcitabine for the Enhanced Tumor Therapy

Sensitization of Non-Small Cell Lung Cancer Cells to Gefitinib and Reversal of Epithelial–Mesenchymal Transition by Aloe-Emodin Via PI3K/Akt/TWIS1 Signal Blockage

Effect of docosahexaenoic acid plus 5-fluorouracil on the drug-resistance associatedprotein of HepG2

Dihydroartemisinin-driven selective anti-lung cancer proliferation by binding to EGFR and inhibition of NRAS signaling pathway-induced DNA damage

A New Epigallocatechin Gallate Derivative Isolated from Anhua Dark Tea Sensitizes the Chemosensitivity of Gefitinib Via the Suppression of PI3K/mTOR and Epithelial-Mesenchymal Transition

The omega-3 polyunsaturated fatty acid docosahexaenoic acid inhibits proliferation and progression of non-small cell lung cancer cells through the reactive oxygen species-mediated inactivation of the PI3K /Akt pathway

Heptadecanoic Acid Inhibits Cell Proliferation in PC‑9 Non‑small‑cell Lung Cancer Cells with Acquired Gefitinib Resistance.

Dihydroartemisinin Inhibits Glucose Uptake and Cooperates with Glycolysis Inhibitor to Induce Apoptosis in Non-Small Cell Lung Carcinoma Cells

Cytochalasin H enhances sensitivity to gefitinib in non-small-cell lung cancer cells through inhibiting EGFR activation and PD-L1 expression

Dihydroartemisinin Suppresses STAT3 Signaling and Mcl-1 and Survivin Expression to Potentiate ABT-263-induced Apoptosis in Non-small Cell Lung Cancer Cells Harboring EGFR or RAS Mutation